

Published in final edited form as:

*J Allergy Clin Immunol.* 2014 February ; 133(2): 577–580.e2. doi:10.1016/j.jaci.2013.09.031.

## Correlation of increased *PARP14* and *CCL26* expression in biopsies from children with eosinophilic esophagitis

Purna Krishnamurthy, MS<sup>a</sup>, Joseph D. Sherrill, PhD<sup>b</sup>, Kalyan Parashette, MD<sup>a</sup>, Shreevrat Goenka, PhD<sup>a</sup>, Marc E. Rothenberg, MD, PhD<sup>b</sup>, Sandeep Gupta, MD<sup>a</sup>, and Mark H. Kaplan, PhD<sup>a</sup>

Mark H. Kaplan: mkaplan2@iupui.edu

<sup>a</sup>Department of Pediatrics, Wells Center for Pediatric Research, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Ind

<sup>b</sup>Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio

### To the Editor

PARP14 is one of 18 poly-ADP ribosyl polymerase (PARP) family members that contain a catalytic domain conferring ADP-ribosyltransferase activity, and was initially identified as a transcriptional cofactor for signal transducer and activator of transcription (STAT)6 activity.<sup>1</sup> Cytokine-stimulated STAT6 DNA binding activates PARP14 catalytic activity, resulting in changes in target gene chromatin.<sup>2</sup> Because STAT6 plays an obligate role in the development of allergic inflammation,<sup>1</sup> and other PARPs including PARP1 may contribute to allergic inflammation,<sup>3</sup> we previously assessed the requirement for PARP14 in the development of allergic inflammation. In a model of allergic airway inflammation, mice deficient in PARP14 had diminished cellular infiltrates, increased lung function, and decreased TH2 cytokine production compared with control mice.<sup>4</sup> Similarly, treatment of wild-type mice with PARP inhibitors during or after the development of disease resulted in decreased airway inflammation, TH2 cell development, and increased lung function compared with control mice.<sup>4</sup> At least part of the mechanism of PARP14 function was through direct effects of PARP14 on TH2 cytokine genes, and the TH2 transcription factor *Gata3*.<sup>4</sup> However, the requirement for PARP14 in STAT6-dependent gene expression in nonlymphoid cells, and whether PARP14 expression is altered in human disease, has not been assessed.

We initially tested whether there are changes in the expression of members of the macro-PARP subfamily of *PARP* genes in children with eosinophilic esophagitis (EoE) compared with control samples. We obtained esophageal biopsies from children with EoE (Indiana University [IU] population; see at [www.jacionline.org](http://www.jacionline.org)) and control samples from children who had esophageal biopsies for diagnostic purposes but did not have eosinophilic esophagitis. RNA was isolated from biopsies, and cDNA was assessed for gene expression by using quantitative PCR. We observed a 5.95-fold average increase in *PARP14*

Disclosure of potential conflict of interest: J. D. Sherrill has received research support from the Thrasher Research Fund. M. E. Rothenberg has received research support from the National Institutes of Health (NIH), the CURED Foundation, the Buckeye Foundation, and FARE; is a board member for the International Eosinophil Society Steering Committee and APFED Medical Panel; has received consulting fees from Immune Pharmaceuticals, Pluristem Pharmaceuticals, Receptos, Inc, and Novartis; has patents (planned, pending, or issued) with Cincinnati Children's Hospital Medical Center; receives royalties from Teva Pharmaceuticals for reslizumab; and has stock/stock options in Immune Pharmaceuticals. S. Gupta has received consulting fees from Meritage Pharma and NPS Pharmaceuticals, and has received lecture fees from Abbott Nutrition. M. H. Kaplan has received research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.

expression, a 3.1-fold average increase in *PARP1* expression, and a decrease in *PARP15* expression in EoE biopsies compared with controls (Fig 1, A). In contrast, there was no significant difference in the expression of *PARP9* (Fig 1, A).

To confirm this finding, we examined *PARP14* expression in a population from Cincinnati Children's Hospital Medical Center through the use of high-throughput RNA sequencing.<sup>5</sup> Compared with the IU population, this population had more severe inflammation<sup>5</sup>. Following analysis of the RNA-sequencing data, we observed similar (4.5-fold) increases in *PARP14* expression as seen in the IU population (Fig 1, B).

The chemokine CCL26 (Eotaxin-3) is a critical component of the pathology of EoE. *CCL26* expression is dramatically increased in biopsies from patients with EoE, and single nucleotide polymorphisms in the *CCL26* gene are associated with increased disease incidence.<sup>6,7</sup> Moreover, STAT6 regulates *CCL26* in esophageal cells.<sup>8</sup> To determine whether *PARP14* expression correlated with *CCL26* expression, we tested the association of expression of these 2 genes in esophageal biopsies from patients with EoE and observed a strong correlation coefficient (IU population:  $R = 0.81$ ;  $P = .0002$ , Cincinnati Children's Hospital Medical Center population:  $R = 0.61$ ,  $P = .03$ ) (Fig 1, C). In contrast, there was no significant correlation between *PARP1* and *CCL26* expression ( $R = 0.30$ ,  $P = .27$ ). There is significant heterogeneity in the expression of *PARP14* in the biopsy samples, with some overlap in the control biopsy samples (Fig 1, A). This heterogeneity was lessened in samples from patients with more severe inflammation (Fig 1, B). Thus, *PARP14* expression is increased and *CCL26* and *PARP14* gene expression is correlated in 2 populations interrogated by 2 distinct methods.

Because our results suggested a relationship between *PARP14* and *CCL26*, we tested the ability of *PARP14* to regulate *CCL26* directly. The esophageal cell line TE-7 was transfected with a *CCL26* luciferase reporter vector and plasmids encoding STAT6 and/or *PARP14* before incubation for 24 hours in the presence or absence of the STAT6-activating cytokines IL-4 and IL-13. Consistent with previous results, transfection of STAT6-expressing plasmids increased *CCL26* reporter activity (Fig 2, A). Moreover, transfection of *PARP14* alone increased basal and cytokine-induced reporter activity (Fig 2, A). Importantly, cotransfection of STAT6 and *PARP14* significantly increased *CCL26* reporter activity over cells transfected with STAT6 alone (Fig 2, A). The effects of *PARP14* expression were entirely dependent on STAT6 binding because they were not observed when the plasmid was cotransfected with a *CCL26* reporter that had a mutation in the STAT6 binding site (Fig 2, A). These results suggested that *PARP14* might be a viable target for modulating the expression of *CCL26*. To test this directly, TE-7 cells were incubated with IL-4 or IL-13 in the presence or absence of the PARP activity inhibitor PJ34 before expression of the endogenous *CCL26* gene was assessed. We observed that IL-4 and IL-13 increased *CCL26* mRNA and that incubation with the PARP inhibitor attenuated the induction in response to either cytokine (Fig 2, B). Similar results were observed in the TE-1 esophageal cell line. Thus, *PARP14*, and PARP activity, contribute to the regulation of *CCL26* in esophageal cells. These results do not exclude the possibility that *PARP14* is expressed by, and functions in, additional cell types that contribute to EoE.

Although we are only beginning to understand the *in vivo* functions of *PARP14*, this report, coupled with our previous work,<sup>4</sup> suggests that *PARP14* has a significant role in the development of allergic inflammation. It likely works in multiple cell types, including in T cells, where it results in increased T<sub>H</sub>2 and T<sub>H</sub>9 development,<sup>4,9</sup> and in target organ epithelial cells, enhancing the production of proallergic chemokines. Our results raise the possibility that targeting *PARP14*, or even PARP activity in general, might be an effective therapy for allergic diseases including EoE.

## METHODS

### Gene expression

RNA was isolated from the esophageal biopsies (IU population), and gene expression was assessed for the indicated genes by using quantitative PCR. The mRNA expression of *CCL26* was determined by using the  $\Delta\text{Ct}$  method. RNA isolated from the Cincinnati Children's Hospital Medical Center population was sequenced at the Cincinnati Children's Hospital Medical Center Gene Discovery and Genetic Variation Core as previously described.<sup>5</sup>

TE-7 esophageal epithelial cells were incubated in the presence or absence of IL-4 (2.5 ng/mL) or IL-13 (20 ng/mL), with or without the PARP inhibitor PJ34 (25  $\mu\text{M}$ ). *CCL26* mRNA expression was assessed by using quantitative PCR.

### Luciferase assay

TE-7 esophageal epithelial cells were transfected with a *CCL26* luciferase reporter or a reporter carrying a mutation in the STAT6 binding site, and control, STAT6-, or PARP14-expressing plasmids. Cells were incubated in the presence or absence of IL-4 (25 ng/mL) or IL-13 (25 ng/mL) for 24 hours before luciferase activity was assessed.


## Acknowledgments

We thank Pierre Hainaut and Jean-Yves Scoazec for supplying esophageal cell lines and the *CCL26* reporter plasmid.


This work was supported by Public Health Service grants R01 AI095282, R01 HL093105, R01 DK076893, and U19 AI070235.

## References

1. Goenka S, Kaplan MH. Transcriptional regulation by STAT6. *Immunol Res.* 2011; 50:87–96. [PubMed: 21442426]
2. Mehrotra P, Riley JP, Patel R, Li F, Voss L, Goenka S. PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation. *J Biol Chem.* 2011; 286:1767–76. [PubMed: 21081493]
3. Rosado MM, Bennici E, Novelli F, Pioli C. Beyond DNA repair, the immunological role of PARP-1 and its siblings. *Immunology.* 2013; 139:428–37. [PubMed: 23489378]
4. Mehrotra P, Hollenbeck A, Riley JP, Li F, Patel RJ, Akhtar N, et al. Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease. *J Allergy Clin Immunol.* 2013; 131:521–31. e1–12. [PubMed: 22841009]
5. Lu TX, Sherrill JD, Wen T, Plassard AJ, Besse JA, Abonia JP, et al. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. *J Allergy Clin Immunol.* 2012; 129:1064–75. e1069. [PubMed: 22391115]
6. Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. *J Clin Invest.* 2006; 116:536–47. [PubMed: 16453027]
7. Gupta SK, Fitzgerald JF, Kondratyuk T, HogenEsch H. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr.* 2006; 42:22–6. [PubMed: 16385249]
8. Lim EJ, Lu TX, Blanchard C, Rothenberg ME. Epigenetic regulation of the IL-13-induced human eotaxin-3 gene by CREB-binding protein-mediated histone 3 acetylation. *J Biol Chem.* 2011; 286:13193–204. [PubMed: 21325281]
9. Goswami R, Jabeen R, Yagi R, Pham D, Zhu J, Goenka S, et al. STAT6-dependent regulation of Th9 development. *J Immunol.* 2012; 188:968–75. [PubMed: 22180613]

**FIG 1.**

Correlation of *PARP14* and *CCL26* expression. **A**, Gene expression was assessed for the indicated genes from IU population biopsies. Results are presented as percent of *BACTIN* control. **B**, *PARP14* expression in CCHMC population biopsies was determined by using RNA sequencing. **C**, The mRNA expression of *CCL26* was graphed against *PAPR14* expression (IU population). Significance was determined by using ANOVA. CCHMC, Cincinnati Children's Hospital Medical Center; NL, normal. \*\*\* $P < 10^{-3}$ . FPKM, fragments per kilobase of transcript per million mapped reads.

**FIG 2.**

PARP14 activates the CCL26 gene. **A**, CCL26 promoter reporter activity with cotransfection of STAT6-and/or PARP14-expressing plasmids into TE-7 esophageal cells.  $*P < .05$ ;  $**P < .001$ , compared with control plasmid transfection;  $\ddagger P < .05$  compared with STAT6 transfection. **B**, CCL26 expression in cytokine-stimulated TE-7 esophageal cells incubated with the PARP inhibitor PJ34. Results are the average of at least 3 experiments.  $*P < .05$ ,  $**P < .001$ , and  $***P < .005$ .  $P$  values determined by using the Student  $t$  test.